Validation of TERA Bio Station T101 of COVID-19 Tested Population.

COVID-19 Clinical Trial

Official title: Pilot Testing Manual For Validation Purposes Providing Clearance for COVID-19 Tested Individuals Using the TERA Bio Station T101

Status Recruiting

Clinical Trial Summary

TERABio Ltd. has developed a rapid screening tool intended to determine if a tested individual is COVID-19-free (Negative to COVID-19).

Clinical Trial Description

The goal of the pilot is to perform a localized validation to the TERA Bio Tests by TERA Bio Station(s). Success Criteria: Clearing at least 80% of the healthy population. Pilot duration: approx. 6-10 work weeks long. Research Population Requirements: Male and Female, age ≥ 18 years old, whose COVID-19 virus infection status is known and verified for at least the last 24 hours (prior to the TERA.Bio test). The study will include a minimum of 300 tested Positive individuals and a minimum of 700 Negative individuals, tested during the 24 hours prior to the TERA.Bio test. Additional PCR tests on specific individuals, based on their symptomatic status and/or their PCR's CT value may be required be done 3 days after taking the breath test. It is expected that each day will contain both Positive and Negative individuals in a similar ratio to the overall expected one (30%). Test Procedure: A staff member will explain to the tested individual about the test and will hand him an informed consent form. The tested individual will review and sign the consent form and return it to the staff member. The individual must sign the informed consent form in order to participate in the pilot testing. The individual's breath sample is then taken by blowing three times into a disposable TERATube. Thereafter, the tube is sealed, sterilized, and scanned by the TERA Bio Station for analysis of its bio-chemical spectral signature. Blind Test objectives and method: Following data analytics of the previous phase and once achieving sufficient testing, a blind test may be performed to validate the accuracy of the TERA.Bio test. The blind test will include 60 individuals from which 30 must be Positive for COVID-19. The blind test's tested individuals will be tested in the exact way the pilot testing was performed and with RT-PCR with the exact same CT. TERA.Bio's team will conduct the breath tests scanning and decoding procedure without obtaining the RT-PCR results in-advance. The TERA.Bio team will send predictions for each tested individual (suspected\negative) to the pilot manager and primary investigator after ALL pilot participants have been tested. The RT-PCR results will then be sent to the TERA.Bio team. The two parties will compare the results obtained from the TERA Bio Station to the results from the RT-PCR. ;

Related Conditions & MeSH terms

• COVID-19

• NCT number: NCT05088902
• Study type: Observational
• Source: Tera Group
• Contact: Nihat Müjdat Hökenek, MD
• Phone: +90 555 320 14 19
• Email: nihathokenek@gmail.com
• Status: Recruiting
• Start date: October 22, 2021
• Completion date: June 30, 2022